Author

P. Dallemagne

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:cancer & tumor microenvironment· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Akhmanova· 1 shared A. Andrieux· 1 shared A. Hans· 1 shared A. Lepailleur· 1 shared a. madeline· 1 shared A. Rai· 1 shared A. Vernet· 1 shared A.-S. Ribba· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Akhmanova

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Dynamic microfluidic single-cell screening identifies pheno-tuning compounds to potentiate tuberculosis therapy

M. Mistretta, M. Cimino, P. Campagne, S. Volant, E. Kornobis, O. Hebert, C. Rochais, P. Dallemagne, C. Lecoutey, C. Tisnerat, A. Lepailleur, Y. Ayotte, S. R. LaPlante, N. Gangneux, M. Zahorszka, , G. Manina

The paper develops a microfluidic platform to screen compounds that reduce bacterial phenotypic variation and enhance tuberculosis drug efficacy.

bioRxiv · Mar 31, 2023Microbiology

Replication of Equine arteritis virus is efficiently suppressed by purine and pyrimidine biosynthesis inhibitors

j.-c. Valle-Casuso, D. Gaudaire, L. Martin-Faivre, a. madeline, P. Dallemagne, S. Pronost, H. Munier-Lehmann, S. Zientara, P.-O. Vidalain, A. Hans

This study identifies three compounds that suppress EAV replication in equine cells, including ribavirin and DHODH inhibitors, offering potential antiviral strategies for EAV outbreaks.

bioRxiv · Apr 10, 2020Microbiology

Two antagonistic microtubule targeting drugs act synergistically to kill cancer cells

L. Peronne, E. Denarier, A. Rai, R. Prudent, A. Vernet, P. Suzanne, S. Ramirez-Rios, S. Michallet, M. Guidetti, J. Vollaire, D. Lucena-Agell, A.-S. Ribba, V. Josserand, J.-L. Coll, P. Dallemagne, , L. Lafanechere

The paper identifies Carba1, a microtubule-destabilizing drug, which synergizes with paclitaxel to enhance cancer cell killing in vitro and in vivo.

bioRxiv · Feb 6, 2020Cancer Biology